FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers worldwide, but current treatment options remain limited and cause serious life-threatening side effects. Aberrant FGFR4 signaling has been validated as an oncogenic driver of HCC, and EZH2, the catalytic subunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yiqi, Zhang, Yibo, Cao, Jieqiong, Su, Zijian, Li, Fu, Zhang, Peiguang, Zhang, Bihui, Liu, Rongzhan, Zhang, Linhao, Xie, Junye, Li, Jingsheng, Zhang, Jinting, Chen, Xiaojia, Hong, An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122280/
https://www.ncbi.nlm.nih.gov/pubmed/37085881
http://dx.doi.org/10.1186/s13046-023-02659-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122280/
https://www.ncbi.nlm.nih.gov/pubmed/37085881
http://dx.doi.org/10.1186/s13046-023-02659-4

Ejemplares similares